the Tobacco group, Philip Morris International, said it had got 22.61% of the respiratory drug developer Vectura in a market purchase based in the U.K.
the Tobacco group, Philip Morris International, said it had got 22.61% of the respiratory drug developer Vectura in a market purchase based in the U.K.